Eisai, Biogen’s Leqembi granted FDA traditional approval to treat Alzheimer’s disease
Leqembi is a humanised immunoglobulin gamma 1 (IgG1) monoclonal antibody therapy, initially approved to treat AD in adults,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Jul 23
Leqembi is a humanised immunoglobulin gamma 1 (IgG1) monoclonal antibody therapy, initially approved to treat AD in adults,…
07 Jul 23
The approval was based on the positive opinion for full marketing authorisation from the Committee for Medicinal Products…
07 Jul 23
Pfizer has acquired around 4.7 million Caribou common shares at a price of $5.33 per share, pursuant to…
07 Jul 23
CorEvitas offers regulatory-grade, real-world evidence solutions to biotechnology and pharmaceutical companies with objective data and clinical insights in…
07 Jul 23
As per the terms of the agreement, F-star and Takeda will jointly conduct research and development activities focused…
07 Jul 23
The SINEFIX implant system introduces a simplified surgical technique specifically tailored for minimally invasive procedures, enabling efficient reattachment…
07 Jul 23
The strategic acquisition is the latest example of the company’s commitment to increasing over-the-counter (OTC) consumer convenience in…
07 Jul 23
The extraordinary regulatory flexibilities covered different areas, including marketing authorisation and related regulatory procedures, manufacturing and importation of…
06 Jul 23
Biocon Biologics has transitioned a portfolio of biosimilars including bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Jul 23
Under the MOU, both firms will improve Thailand’s capacity for vaccine development and production and will also work…